Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nemolizumab in Prurigo Nodularis
NCT03181503Phase 2Completed
- Sponsor
- Galderma
- Start
- Oct 2017
- Primary completion
- Sep 2018
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in prurigo nodularis (PN) comparing Placebo with Nemolizumab 0.5 mg/kg (2 arms). Primary endpoint: Percent Change From Baseline in Weekly Average of the Peak Pruritus Numeric Rating Scale Score at 4 weeks. Started Oct 2017; status: completed.
02
Drugs
nemolizumab
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on NCT03181503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03181503.